Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cat. No. EC93112520 A2780ADR (Ovary, human) Culture Medium : RPMI 1640 + 2 mM Glutamine + 10% Fetal Bovine Serum (FBS); treatment with 10- 7M adriamycin at least once a week. Cell Line description : The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (catalogue no.EC93112519) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastin. To retain resistance adriamycin has to be added to the media at least once a month. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. A2780ADR do not possess the P-170 glycoprotein associated with pleiotropic drug resistance in murine tumors. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer. DESCRIPTION OF REPOSITORY REFERENCE SEED STOCK Morph ology : Epithelial. Sub Culture Routine : Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5×1,000 to 2 × 10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO 2; 37℃. Recommendation: culture cells without drug after resuscitation until growth has been fully established. Karyotype : Not specified. Depositor : Dr T H Ward, Cell Culture Unit, Patterson Laboratories, Chrustie Hospital, Manchester Originator : Yes. Country : UK References : Proc Amer Assoc Cancer Res 1984; 25: 336. Seminars in Oncology 1984; 11: 285.